Heat shock protein gp96 is a kind of tumor antigen complex with specific immune function, which contains the patient’s unique tumor “antigen fingerprint information”. It contains patient-specific tumor “antigen fingerprint information”, which can be injected into patients to target and destroy tumor cells containing this “fingerprint information” without affecting normal tissues, and has less toxic side effects than general cytotoxic drugs. Heat shock protein gp96 autoimmunotherapy (gp96 autoimmunotherapy) is a medical technology that extracts heat shock protein gp96 from the patient’s own tumor tissue and infuses it back into the patient’s body by subcutaneous injection to activate the specific anti-tumor T-cell immune response, which can kill and remove the residual tumor cells after surgery to prevent tumor recurrence and metastasis, prolong the patient’s life and improve the quality of survival. Although surgery can remove the primary tumor, there may still be a small amount of residual tumor cells in the patient’s body, and they will grow rapidly under suitable conditions, which is the main reason for tumor recurrence and serious life-threatening tumors. Since the 1990s, foreign scholars began to try to use the heat shock protein gp96 autoimmunotherapy technology for the treatment of human malignant tumors, and have so far obtained and published data on its efficacy and safety in several fields such as glioma, renal cell carcinoma, and melanoma. Based on these data, gp96 immunotherapy technology has been approved as an orphan drug by FDA (Food and Drug Administration) for the treatment of glioma, melanoma and kidney cancer in the U.S., and by EMEA (European Medicines Agency) for the treatment of glioma and kidney cancer in the EU, and was approved for the treatment of kidney cancer in Russia in 2008. In April 2009, the World Vaccine Congress evaluated “heat shock protein gp96 autologous tumor immunotherapy” as the best autologous immunotherapy technology for tumors.